7039-76-1

Basic information

• Product Name: 2-BROMO-1-(5-BROMO-1-BENZOFURAN-2-YL)-1-ETHANONE
• Synonyms: 2-BROMO-1-(5-BROMO-1-BENZOFURAN-2-YL)-1-ETHANONE;2-BROMO-1-(5-BROMO-1-BENZOFURAN-2-YL)ETHANONE;2-Bromo-(5-bromo-1-benzofuran-2-yl)ethan-1-one;5-Bromo-2-bromoacetyl-1-benzofuran;2-bromo-1-(5-bromobenzo[b]furan-2-yl)ethanone;2-Bromo-(5-bromo-1-benzofuran-2-yl)ethan-1-one 97%;2-Bromo-(5-bromo-1-benzofuran-2-yl)ethan-1-one97%
• CAS NO: 7039-76-1
• Molecular Formula: C₁₀H₆Br₂O₂
• Molecular Weight: 317.96
• Mol File: 7039-76-1.mol
• Article Data: 10

Chemical Properties

• Melting Point: 140 °C
• Boiling Point: 360.9°C at 760 mmHg
• Flash Point: 172°C
• Appearance: /
• Density: 1.901g/cm³
• Vapor Pressure: 2.16E-05mmHg at 25°C
• Refractive Index: 1.661
• CAS DataBase Reference: 2-BROMO-1-(5-BROMO-1-BENZOFURAN-2-YL)-1-ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-1-(5-BROMO-1-BENZOFURAN-2-YL)-1-ETHANONE(7039-76-1)
• EPA Substance Registry System: 2-BROMO-1-(5-BROMO-1-BENZOFURAN-2-YL)-1-ETHANONE(7039-76-1)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 7039-76-1(Hazardous Substances Data)

Usage

General Description

2-Bromo-1-(5-bromo-1-benzofuran-2-yl)-1-ethanone is a chemical compound containing a benzofuran ring and bromine atoms. It is commonly used as an intermediate in organic synthesis and pharmaceutical research. 2-BROMO-1-(5-BROMO-1-BENZOFURAN-2-YL)-1-ETHANONE is known for its potential biological activities, including antimicrobial and anti-inflammatory properties. It is also widely used in the preparation of various pharmaceuticals and agrochemicals. Its unique structure and properties make it a valuable tool in medicinal chemistry and drug discovery. However, it is important to handle this compound with care, as it is potentially hazardous and should be used in a controlled laboratory environment.

InChI:InChI=1/C10H6Br2O2/c11-5-8(13)10-4-6-3-7(12)1-2-9(6)14-10/h1-4H,5H2

Upstream product

• 38220-75-6 2-acetyl-5-bromobenzo[b]furan 
• 1761-61-1 5-bromosalicyclaldehyde 

Downstream Products

• 1254170-67-6 4-(5-bromobenzofuran-2-yl)-2-(2-chloro-6-fluorophenyl)-1H-imidazole 
• 1412901-14-4 (5-bromo-benzofuran-2-yl)-{4-phenyl-5-[(1-pyridin-2-ylethylidene)hydrazono]-4,5-dihydro-[1,3,4]thiadiazol-2-yl}methanone 
• 1412901-15-5 2-{[5-(5-bromo-benzofuran-2-carbonyl)-3-phenyl-3H-[1,3,4]thiadiazol-2-ylidene]hydrazono}indan-1,3-dione 
• 1412901-16-6 5-[(5-bromo-1-benzofuran-2-yl)carbonyl]-3-phenyl-1,3,4-thiadiazol-2(3H)-one cyclopentylidenehydrazone 
• 1412901-17-7 5-[(5-bromo-1-benzofuran-2-yl)carbonyl]-3-phenyl-1,3,4-thiadiazol-2(3H)-one cyclohexylidenehydrazone 
• 1412901-18-8 5-[(5-bromo-1-benzofuran-2-yl)carbonyl]-3-phenyl-1,3,4-thiadiazol-2(3H)-one cycloheptylidenehydrazone 
• 1412900-75-4 (5-bromo-1-benzofuran-2-yl)[4-phenyl-5-(phenylimino)-4,5-dihydro-1,3,4-thiadiazol-2-yl]methanone 
• 1412900-76-5 ethyl 3-(5-bromo-benzofuran-2-carbonyl)-7-methyl-1,5-diphenyl-1,5-dihydro-[1,2,4]triazolo[4,3-a]pyrimidine-6-carboxylate 
• 1412900-77-6 ethyl 3-(5-bromo-benzofuran-2-carbonyl)-7-methyl-1-phenyl-5-p-tolyl-1,5-dihydro-[1,2,4]triazolo[4,3-a]pyrimidine-6-carboxylate 
• 1412900-78-7 ethyl 3-(5-bromo-benzofuran-2-carbonyl)-5-(4-methoxyphenyl)-7-methyl-1-phenyl-1,5-dihydro-[1,2,4]triazolo[4,3-a]pyrimidine-6-carboxylate 
• 1412900-79-8 ethyl 3-(5-bromo-benzofuran-2-carbonyl)-5-(4-chlorophenyl)-7-methyl-1-phenyl-1,5-dihydro-[1,2,4]triazolo[4,3-a]pyrimidine-6-carboxylate 
• 1412900-80-1 ethyl 3-(5-bromo-benzofuran-2-carbonyl)-5-(2,3-dimethoxy-phenyl)-7-methyl-1-phenyl-1,5-dihydro-[1,2,4]triazolo[4,3-a]pyrimidine-6-carboxylate 
• 1412900-81-2 ethyl 5-benzo[1,3]dioxol-4-yl-3-(5-bromobenzofuran-2-carbonyl)-7-methyl-1-phenyl-1,5-dihydro-[1,2,4]triazolo[4,3-a]pyrimidine-6-carboxylate 
• 1412900-82-3 ethyl 3-(5-bromo-benzofuran-2-carbonyl)-5-(4-isopropylphenyl)-7-methyl-1-phenyl-1,5-dihydro-[1,2,4]triazolo[4,3-a]pyrimidine-6-carboxylate 

Relevant articles and documents

Synthesis and Anti-Cholinesterase Activity of Novel Glycosyl Benzofuranylthiazole Derivatives

Abstract: A new series of glycosyl benzofuranylthiazole derivatives were designed, synthesized, characterized, and evaluated as potential candidates to treat Alzheimer’s disease. The compounds have been synthesized by the cyclocondensation of glycosyl thiourea with a variety of 2-(bromoacetyl)benzofurans. The reaction conditions have been optimized, and good yields (79–95%) have been obtained. The synthesized compounds showed different degrees of cholinesterase inhibitory activity.

Synthesis and bioactivity of novel C2-glycosyl benzofuranylthiazoles derivatives as acetylcholinesterase inhibitors

A new series of C2-glycosyl benzofuranylthiazole derivatives was synthesised by the further cyclization of glycosyl thiourea and 2-(bromoacetyl)-benzofuran via Hantzsch’s method. The corresponding 2-(bromoacetyl)-benzofuran derivatives were obtained by the reaction from various salicylaldehydes, and the glycosyl thiourea was prepared through a series of steps from D-Glucosamine. The acetylcholinesterase-inhibitory activities of the products were tested by Ellman’s method. The most active compounds were subsequently evaluated for the 50% inhibitory concentration values. N-(1,3,4,6-tetra-O-benzyl-2-deoxy-β-D-glucopyranosyl)-4-(5-methoxy-benzofuran-2-yl)-1,3-thiazole-2-amine possessed the best acetylcholinesterase-inhibition activity with a 50% inhibitory concentration of 2.03 ± 0.26 μM.

Biologically Active Heterocyclic Hybrids Based on Quinazolinone, Benzofuran and Imidazolium Moieties: Synthesis, Characterization, Cytotoxic and Antibacterial Evaluation

Cytotoxic and antimicrobial agents structurally based on quinazolinone, benzofuran and imidazole pharmacophores, have been designed and synthesized. Spectral (IR, 1H-NMR) and elemental analysis data established the structures of these novel 3-[1-(1-benzofuran-2-yl)-2-(4-oxoquinazolin-3(4H)-yl)ethyl]-1-methyl-1H-imidazol-3-ium chloride hybrid derivatives. All the synthesized compounds were evaluated for in?vitro cytotoxicity and antimicrobial activities. Cytotoxic evaluation using MTT assay revealed that compounds 12c, 12g and 12i exhibited significant cytotoxicity with IC50 values 1, 1, and 0.57?μm on this cell line, respectively. Biological activity of the synthesized compounds as antibacterial agent were also evaluated against three Gram-negative (Escherichia coli, Pseudomonas aeruginosa and Salmonella typhi), three Gram-positive (Staphylococcus aureus, Bacillus subtilis and Listeria monocitogenes) and one yeast-like fungi (Candida albicans) strains. All compounds 12a?–?12i showed slightly higher activity against Gram-positive bacteria than the Gram-negative one. Among the nine new compounds screened, 3-[1-(5-bromo-1-benzofuran-2-yl)-2-(6-chloro-4-oxoquinazolin-3(4H)-yl)ethyl]-1-methyl-1H-imidazol-3-ium chloride (12e) has pronounced higher antimicrobial activity against all tested strains. These results demonstrated potential importance of molecular hybridization in the development of new lead molecules with major cytotoxicity and antimicrobial activity.